• Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
    • Mergers & Acquisitions
  • Value-based Care
    • ACO

RXQ Compounding Raises $7M for FDA Approved 503B Outsourcing Facility

by Fred Pennic 07/24/2018 Leave a Comment

Share with your friends










Submit

RXQ Compounding Raises $7M for FDA Approved 503B Outsourcing Facility

RXQ Compounding, LLC, an Athens, Ohio-based manufacturer of sterile and non-sterile medications licensed to ship to 38 states and Washington, D.C., announced it has raised $7 million in Series A funding led by Ohio Innovation Fund (OIF). RXQ plans to use the latest round of funding to open a new state-of-the-art FDA 503B outsourcing facility  for pharmacy compounding, employing hundreds in the Appalachian area of Southeast Ohio. RXQ Compounding, LLC is poised to be a leader in the new paradigm of manufacturing facilities across the country.

The company has seen revenue growth of approximately 200 percent over the past two years. With this Series A funding the company will continue to grow its product line and secure additional and larger partnerships with customers, all with advanced systems and processes to maintain the highest of FDA standards. RXQ currently works with more than 500 customers, with a reorder rate of nearly 100 percent.  

RXQ Compounding manufactures sterile and non-sterile medications including products that are on the FDA Short List. These medications are provided to physician offices and hospitals across the United States in various sized vials and syringes.  RXQ currently manufactures more than 140 products, including:

– Sterile and non-sterile injectables

– Veterinary medications

– Dermatologic creams and ointments

– Ophthalmic solutions

– Orthopedic steroids

– Custom production for hospitals

It is currently licensed to ship to 38 states and Washington, D.C., with licenses for other states on the horizon. RXQ’s products do not require a patient prescription and can be used for office use. As an FDA 503B Outsourcing Facility, RXQ is required by the FDA to follow Current Good Manufacturing Processes (CGMP), which include sterility, potency, and endotoxins.

“This investment will help RXQ open a new world-class compounding facility, boosting our ability to further serve our customers and expand our line of products,” said Ed Zatta, Chief Executive Officer of RXQ Compounding. “We’re excited to be supported by OIF, which has a proven track record in the region, including multiple IPOs and major acquisitions in both the technology and medical technology industries.”

Share with your friends










Submit

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

« Click Therapeutics Lands $17M to Advance Prescription Digital Therapeutics Platform
Madaket Health Raises $10M for Automated Healthcare Provider Enrollment Platform »

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Recent Articles

  • Why Interoperability Cannot Be Solved with Homogenous EHRs

    5 Reasons Why A Single, Integrated EHR Will Not Solve Interoperability

    ... more
  • SubjectWell, Human API Partner to Provide Free Patient Medical Record Retrieval

    SubjectWell, Human API Partner to Provide Free Patient Medical Record Retrieval

    -... more
  • Cleveland Clinic London Taps Vocera to Build Clinical Communications Platform

    Cleveland Clinic London Taps Vocera to Build Clinical Communications Platform

    -... more

Most Read

  • Dedalus to Acquire Agfa’s HCIS Business: Impact on European EMR Market Dedalus to Acquire Agfa’s HCIS Business: Impact on European EMR Market
  • Healthcare Breach Report 2016 6 Ways Health Informatics Is Transforming Health Care
  • Konica Minolta Deploys AI Robots to Support Patient Care at Hospital in Italy The Growing Emergence of Robots in Healthcare: Key Opportunities & Benefits
  • Cleveland Clinic London Taps Vocera to Build Clinical Communications Platform Cleveland Clinic London Taps Vocera to Build Clinical Communications Platform
  • Digital Health - Is It Worth It? How to Calculate ROI in Digital Health Digital Transformation In Healthcare Is Not Happening As Fast As It Should — And There’s One Reason No One is Talking About
  • Waystar Acquires Recondo Technology Waystar Acquires AI-Powered Revenue Cycle Platform Recondo Technology
  • Philips, Humana Partner on 2 Pilot Programs to Improve Care for At-Risk Medicare Advantage Members
  • Elevating The Hospital Room Waiting Experience: 6 Facets to Consider Elevating The Hospital Room Waiting Experience: 6 Factors to Consider
  • Top 10 Challenges, Issues and Opportunities for Healthcare Executives in 2019 Top 10 Challenges, Issues and Opportunities Healthcare Executives Will Face in 2020
  • The State of Value-based Care in 2018: 10 Key Trends to Know The State of Value-based Care in 2018: 10 Key Trends to Know

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2020 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2019. HIT Consultant Media. All Rights Reserved. Privacy Policy |